On May 3, 2022, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, California) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France). An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Development Summit (May 24 to 26 in Boston, Massachusetts). [Editor’s Note: MSC-NTF is mesenchymal stem cells-neurotrophic factors; CSF is cerebrospinal fluid.]
Login Or Register To Read Full Story